Stryker announces definitive agreement to acquire Inari Medical (NARI) for $80/share in cash, a total of ~$4.9 bln, providing entry into high-growth peripheral vascular segment (361.36 -0.16)
- Inari (NARI), which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism to Stryker.
- Inari's innovative product portfolio is highly complementary to Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.
- The transaction is anticipated to close by the end of the first quarter of 2025, subject to customary closing conditions. Expected impacts to 2025 financial results will be discussed on Stryker's upcoming fourth quarter 2024 earnings call scheduled for January 28, 2025.